Pharmacologic Treatment Augmentation in Chronic Depression (Ket+CBASP)

This randomised, controlled, double-blinded, Phase II study (n=60) investigates the pharmacological augmentation of chronic depression treatment using ketamine.

Conducted by University Hospital Tuebingen, the trial targets adults aged 18 to 64 exhibiting chronic depression at therapy resistance stage 2, despite previous unsuccessful treatment attempts with at least two antidepressants and a minimum of 12 psychotherapy sessions.

Participants are randomly assigned to one of three treatment groups: Ketamine +CBASP, Ketamine +TAU, or Placebo +CBASP. The study employs a combination of psychotherapeutic treatment and either ketamine infusions or placebo, with regular data collection including psychological assessments, blood samples, and MRI scans.

Primary outcome measures include changes in depressive symptoms assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS).

The study aims to evaluate treatment efficacy and safety, correlating changes in symptoms with various factors such as session contents, psychosocial support, and antidepressant medication. Last updated in May 2024, this trial is not yet recruiting participants.

Topic Depression
Compound Ketamine Placebo
Country Germany
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.